UNITED STATES

 

 

SECURITIES AND EXCHANGE
COMMISSION

 

 

Washington, D.C. 20549

 

 

SCHEDULE 13D/A

 

Under the Securities Exchange Act of 1934
(Amendment No. 4)* 

Flamel Technologies, S.A.

(Name of Issuer)

 

Ordinary Shares

(Title of Class of Securities)

 

338488 109

(CUSIP Number)

 

Hope Flack
BVF Partners L.P.
900 North Michigan Avenue, Suite 1100
Chicago, Illinois 60611
(312) 506-6500

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

 

September 14, 2006

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 



 

CUSIP No.  338488 109

 

 

1.

Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
Biotechnology Value Fund, L.P.

 

 

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

 

(a)

 ý

 

 

(b)

 o

 

 

3.

SEC Use Only

 

 

4.

Source of Funds (See Instructions)
Not Applicable

 

 

5.

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)     o

 

 

6.

Citizenship or Place of Organization
Delaware

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

7.

Sole Voting Power
0

 

8.

Shared Voting Power 
301,197

 

9.

Sole Dispositive Power 
0

 

10.

Shared Dispositive Power 
301,197

 

 

11.

Aggregate Amount Beneficially Owned by Each Reporting Person 
301,197

 

 

12.

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   o

 

 

13.

Percent of Class Represented by Amount in Row (11) 
1.3%

 

 

14.

Type of Reporting Person (See Instructions)
PN

 

2



 

 

1.

Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
Biotechnology Value Fund II, L.P.

 

 

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

 

(a)

 ý

 

 

(b)

 o

 

 

3.

SEC Use Only

 

 

4.

Source of Funds (See Instructions)
Not Applicable

 

 

5.

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)     o

 

 

6.

Citizenship or Place of Organization
Delaware

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

7.

Sole Voting Power
0

 

8.

Shared Voting Power 
367,670

 

9.

Sole Dispositive Power 
0

 

10.

Shared Dispositive Power 
367,670

 

 

11.

Aggregate Amount Beneficially Owned by Each Reporting Person 
367,670

 

 

12.

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   o

 

 

13.

Percent of Class Represented by Amount in Row (11) 
1.5%

 

 

14.

Type of Reporting Person (See Instructions)
PN

 

3



 

 

1.

Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
BVF Investments, L.L.C.

 

 

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

 

(a)

 ý

 

 

(b)

 o

 

 

3.

SEC Use Only

 

 

4.

Source of Funds (See Instructions)
Not Applicable

 

 

5.

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)     o

 

 

6.

Citizenship or Place of Organization
Delaware

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

7.

Sole Voting Power
0

 

8.

Shared Voting Power 
560,500

 

9.

Sole Dispositive Power 
0

 

10.

Shared Dispositive Power 
560,500

 

 

11.

Aggregate Amount Beneficially Owned by Each Reporting Person 
560,500

 

 

12.

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   o

 

 

13.

Percent of Class Represented by Amount in Row (11) 
2.4%

 

 

14.

Type of Reporting Person (See Instructions)
OO

 

4



 

 

1.

Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
Investment 10, L.L.C.

 

 

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

 

(a)

 ý

 

 

(b)

 o

 

 

3.

SEC Use Only

 

 

4.

Source of Funds (See Instructions)
Not Applicable

 

 

5.

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)     o

 

 

6.

Citizenship or Place of Organization
Illinois

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

7.

Sole Voting Power
0

 

8.

Shared Voting Power 
82,820

 

9.

Sole Dispositive Power 
0

 

10.

Shared Dispositive Power 
82,820

 

 

11.

Aggregate Amount Beneficially Owned by Each Reporting Person 
82,820

 

 

12.

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   o

 

 

13.

Percent of Class Represented by Amount in Row (11) 
0.4%

 

 

14.

Type of Reporting Person (See Instructions)
OO

 

5



 

 

1.

Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
BVF Partners L.P.

 

 

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

 

(a)

 ý

 

 

(b)

 o

 

 

3.

SEC Use Only

 

 

4.

Source of Funds (See Instructions)
Not Applicable

 

 

5.

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)     o

 

 

6.

Citizenship or Place of Organization
Delaware

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

7.

Sole Voting Power
0

 

8.

Shared Voting Power 
1,312,187

 

9.

Sole Dispositive Power 
0

 

10.

Shared Dispositive Power 
1,312,187

 

 

11.

Aggregate Amount Beneficially Owned by Each Reporting Person 
1,312,187

 

 

12.

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   o

 

 

13.

Percent of Class Represented by Amount in Row (11) 
5.5%

 

 

14.

Type of Reporting Person (See Instructions)
PN

 

6



 

 

1.

Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
BVF Inc.

 

 

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

 

(a)

 ý

 

 

(b)

 o

 

 

3.

SEC Use Only

 

 

4.

Source of Funds (See Instructions)
Not Applicable

 

 

5.

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)     o

 

 

6.

Citizenship or Place of Organization
Delaware

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

7.

Sole Voting Power
0

 

8.

Shared Voting Power 
1,312,187

 

9.

Sole Dispositive Power 
0

 

10.

Shared Dispositive Power 
1,312,187

 

 

11.

Aggregate Amount Beneficially Owned by Each Reporting Person 
1,312,187

 

 

12.

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   o

 

 

13.

Percent of Class Represented by Amount in Row (11) 
5.5%

 

 

14.

Type of Reporting Person (See Instructions)
IA, CO

 

7



 

This Amendment No. 4 to Schedule 13D amends the Statement on Schedule 13D (the "Schedule 13D") filed with the Securities and Exchange Commission on April 21, 2005 by the Reporting Persons, as amended on July 19, 2005, January 13, 2006 and April 25, 2006, and is being filed by the Reporting Persons to disclose a decrease of more than 1% in their beneficial ownership of the Ordinary Shares.


Capitalized terms used herein and not defined herein have the meanings ascribed to them in the Schedule 13D. Except as specifically set forth herein, the information set forth in the Schedule 13D remains unchanged.


The Schedule 13D is hereby amended as follows:

 

Item 5.

Interest in Securities of the Issuer

Item 5 is hereby amended and restated to read in its entirety as follows:


The Reporting Persons’ percentage ownership of the Ordinary Shares is based on 23,811,090 shares being outstanding, as reported in Flamel's Report on Form 6-K for the month of August 2006.

 

(a)           BVF beneficially owns 301,197 Ordinary Shares, BVF2 beneficially owns 367,670 Ordinary Shares, Investments beneficially owns 560,500 Ordinary Shares, ILL10 beneficially owns 82,820 Ordinary Shares and each of Partners and BVF Inc. beneficially owns 1,312,187 Ordinary Shares, representing percentage ownership of approximately 1.3%, 1.5%, 2.4%, 0.4% and 5.5%, respectively.

 

8



 

(b)           Each of BVF, BVF2, Investments and ILL10 shares with Partners voting and dispositive power over the Ordinary Shares each such entity beneficially owns. Partners and BVF Inc. share voting and dispositive power over the 1,312,187 Ordinary Shares they beneficially own with BVF, BVF2 and Investments, and ILL10.

 

(c)           The following sales of Ordinary Shares have been made in the last sixty (60) days by the following Reporting Persons.


Sales of Ordinary Shares

Reporting Person
BVF

Date

09/14/2006

Shares Sold

58,000

Sales Price

$18.25

    
    

Reporting Person
BVF2

Date

09/14/2006

Shares Sold

42,000

Sales Price

$18.25

    


 

All of the above listed transactions were open market sales effected through Merrill Lynch & Co.

 

9



 

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated:  September 18, 2006

 

BIOTECHNOLOGY VALUE FUND, L.P.

 

 

 

 

 

By:

BVF Partners L.P., its general partner

 

 

 

 

 

 

 

By:

BVF Inc., its general partner

 

 

 

 

 

 

 

 

 

By:

/s/ Mark N. Lampert

 

 

 

 

Mark N. Lampert

 

 

 

President

 

 

 

 

 

 

 

 

 

 

BIOTECHNOLOGY VALUE FUND II, L.P.

 

 

 

 

 

By:

BVF Partners L.P., its general partner

 

 

 

 

 

 

 

By:

BVF Inc., its general partner

 

 

 

 

 

 

 

 

 

By:

/s/ Mark N. Lampert

 

 

 

 

Mark N. Lampert

 

 

 

President

 

 

 

 

 

 

 

 

 

 

BVF INVESTMENTS, L.L.C.

 

 

 

 

 

By:

BVF Partners L.P., its manager

 

 

 

 

 

 

 

By:

BVF Inc., its general partner

 

 

 

 

 

 

 

 

 

By:

/s/ Mark N. Lampert

 

 

 

 

Mark N. Lampert

 

 

 

President

 

 

 

 

 

 

 

 

 

 

INVESTMENT 10, L.L.C.

 

 

By:

BVF Partners L.P., its attorney-in-fact

 

 

 

 

 

 

 

By:

BVF Inc., its general partner

 

 

 

 

 

 

 

 

 

By:

/s/ Mark N. Lampert

 

 

 

 

Mark N. Lampert

 

 

 

President

 

 

 

10



 

BVF PARTNERS L.P.

 

 

 

 

 

By:

BVF Inc., its general partner

 

 

 

 

 

 

 

By:

/s/ Mark N. Lampert

 

 

 

 

Mark N. Lampert

 

 

 

President

 

 

 

 

 

 

 

 

 

 

BVF INC.

 

 

 

 

 

By:

/s/ Mark N. Lampert

 

 

 

 

Mark N. Lampert

 

 

 

President

 

 

 

 

 

 

 

11